These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37703955)

  • 1. Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization.
    Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
    Int J Pharm; 2023 Oct; 645():123411. PubMed ID: 37703955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection.
    Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
    Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.
    Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
    Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
    Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.
    Momin MAM; Rangnekar B; Sinha S; Cheung CY; Cook GM; Das SC
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
    Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749
    [No Abstract]   [Full Text] [Related]  

  • 8. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
    Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
    Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated continuous manufacturing of inhalable remdesivir nanoagglomerate dry powders: Design, optimization and therapeutic potential for respiratory viral infections.
    Chan HW; Lee HW; Chow S; Lam DCL; Chow SF
    Int J Pharm; 2023 Sep; 644():123303. PubMed ID: 37579825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
    Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
    Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.
    Sahakijpijarn S; Moon C; Koleng JJ; Christensen DJ; Williams Iii RO
    Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
    Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ; Worth Longest P; Hindle M
    Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray dried inhalable ivacaftor co-amorphous microparticle formulations with leucine achieved enhanced in vitro dissolution and superior aerosol performance.
    Guan J; Yuan H; Yu S; Mao S; Tony Zhou Q
    Int J Pharm; 2022 Jun; 622():121859. PubMed ID: 35643348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization.
    Eedara BB; Fan C; Sinha S; Khadka P; Das SC
    Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
    Momin MAM; Sinha S; Tucker IG; Das SC
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.